 |
Pharmacyclics PCYC (news,
chart,
quote) - PCYC January Option implied Volatility above 200 prior to Phase 3 Data
PCYC's Phase 3 results for its lead drug Xcytrin to treat non-small cell lung cancer patients with brain metastases in combination with whole brain radiation therapy is expected to be released in December. PCYC January option implied volatility is above 200. Above average option implied volatility suggests large price fluctuations or risk.
|
|
|
|
